Yahoo · Aug 20, 2026
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain With enrollment and treatment completed, ADAPT-related clinical execution expenses are expected to decrease as the program transitions into follow-up, data maturation and regulatory planning Company believes reduced enrollment- and treatment-related expenditures should help pres
